S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This Stock Could Go Up 66% or More. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
Better Than Oil Stocks? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This Stock Could Go Up 66% or More. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
Better Than Oil Stocks? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This Stock Could Go Up 66% or More. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
Better Than Oil Stocks? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This Stock Could Go Up 66% or More. (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
Better Than Oil Stocks? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
OTCMKTS:CPHRF

Cipher Pharmaceuticals (CPHRF) Stock Forecast, Price & News

$3.18
-0.05 (-1.55%)
(As of 09/28/2023 ET)
Compare
Today's Range
$2.50
$3.19
50-Day Range
$2.56
$3.34
52-Week Range
$1.31
$5.38
Volume
9,000 shs
Average Volume
6,536 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CPHRF stock logo

About Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

CPHRF Price History

CPHRF Stock News Headlines

Cipher Pharmaceuticals (CPHRF) Receives a Buy from Stifel Nicolaus
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Cipher Pharmaceuticals earnings: here's what Wall Street expects
Cipher Pharmaceuticals Inc. (CPHRF)
Cipher Pharmaceuticals Inc stock boosted on Friday.
See More Headlines
Receive CPHRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPHRF Company Calendar

Last Earnings
5/05/2016
Today
9/29/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CPHRF
Previous Symbol
NASDAQ:CPHR
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Craig J. Mull
    Interim CEO & Chairman
  • Mr. Bryan Jacobs
    Chief Financial Officer
  • Dr. Diane Gajewczyk
    VP of Scientific & Medical Affairs
  • Mr. Emilio Presti
    Director of Sales & Marketing













CPHRF Stock - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPHRF shares.
View CPHRF analyst ratings
or view top-rated stocks.

How have CPHRF shares performed in 2023?

Cipher Pharmaceuticals' stock was trading at $2.7949 at the beginning of 2023. Since then, CPHRF shares have increased by 13.9% and is now trading at $3.1847.
View the best growth stocks for 2023 here
.

Are investors shorting Cipher Pharmaceuticals?

Cipher Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,100 shares, a drop of 15.4% from the August 31st total of 1,300 shares. Based on an average trading volume of 16,300 shares, the short-interest ratio is currently 0.1 days.
View Cipher Pharmaceuticals' Short Interest
.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The company earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million.

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $3.18.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at (905) 602-5840.

This page (OTCMKTS:CPHRF) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -